IOmx Therapeutics

What IOmx Therapeutics does

iOmx Therapeutics AG is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Martinsried near Munich, Germany. The company develops biomarker-enabled cancer immunotherapies that target immune evasion mechanisms orthogonal to the established PD-1/PD-L1 axis. Its discovery engine is the proprietary iOTarg™ systematic screening platform, which interrogates tumor cells for novel immune checkpoint targets and was used to identify SIK3 as a previously unrecognized checkpoint regulator. Pipeline assets include OMX-0407, an orally bioavailable first-in-class spectrum-selective inhibitor of SIK and other oncology-relevant tyrosine kinases currently in Phase I/II trials (NCT05826600) for solid tumors such as angiosarcoma and renal cell carcinoma; IOMX-0675, a fully human LILRB1/LILRB2 dual-targeting antibody that spares activating family members LILRA1/LILRA3 and is now in clinical development following CTA approval in April 2025; IOMX-0235, a Fc-enhanced CCR9 monoclonal antibody in lead optimization for inflammatory bowel disease; and discovery-stage tri-functional bispecifics and T cell engagers.

The company's revenue model is structured around future licensing deals, co-development partnerships with pharmaceutical companies, milestone payments, and royalties; there is no approved product, no disclosed pricing, and no commercial sales organization. End-customers are oncology and IBD patients reached through partners, while business counterparties are large pharmaceutical and biotech firms seeking differentiated immuno-oncology assets. iOmx is privately held and venture-capital-backed, with a disclosed EUR 65 million Series B round in October 2021 led by Athos Service GmbH and MIG Capital AG, alongside Sofinnova Partners, Wellington Partners, M Ventures (Merck KGaA's CVC), and Arvantis Group, totaling approximately EUR 110 million+ in disclosed funding.

The go-to-market motion is enterprise-focused, leveraging scientific conferences (e.g., AACR 2024), peer-reviewed publications, and direct engagement with pharmaceutical business development teams to secure co-development and licensing transactions. Operating geographies are anchored in the DACH region, with clinical trials conducted globally. Key executive leadership comprises CEO Apollon Papadimitriou (formerly Roche Innovation Center Munich), COO Hannes Loferer, CDO Christine Rothe (formerly MorphoSys and Pieris), CFO Florian Schmid (appointed June 2024), and CMO Tiantom Jarutat, a team with concentrated oncology drug development experience across Roche, MorphoSys, Pieris, GSK, and Sotio.

Name

IOmx Therapeutics

Legal name

iOmx Therapeutics AG

Website

https://iomx.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

iOmx Therapeutics AG is a clinical-stage German biotech developing biomarker-enabled cancer immunotherapies against novel immune checkpoints identified via its proprietary iOTarg™ screening platform, with lead SIK inhibitor OMX-0407 in Phase I/II trials and a LILRB1/LILRB2 antibody entering the clinic.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Cancer immunotherapy
• Immuno-oncology therapeutics
• Monoclonal antibody development
• Immune checkpoint inhibitors
• Bispecific antibody platforms

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: IO.mx develops novel cancer immunotherapies through clinical stages and generates revenue through licensing deals, co-development partnerships, and eventual commercialization of drug candidates. The company is currently in clinical development with OMX-0407 in Phase I/II trials.
2. Strategic Partnerships and Co-development: The company pursues strategic partnerships with pharmaceutical companies for co-development and commercialization of its pipeline programs, generating upfront payments, milestone payments, and royalty streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

iOmx Therapeutics is a clinical-stage biotech company that develops next-generation cancer immunotherapies targeting novel immune checkpoints beyond the PD-1/PD-L1 axis. The company's pipeline includes biomarker-enabled drug candidates such as the SIK inhibitor OMX-0407 (Phase I/II), the dual-targeting LILRB1/LILRB2 antibody IOMX-0675 (IND-enabling), and the CCR9 antibody IOMX-0235 for inflammatory bowel disease. Its discovery programs include tri-functional bispecific antibodies and T cell engagers, all supported by the proprietary iOTarg™ screening platform.

Product overview

iOmx Therapeutics is a clinical-stage biotech company developing a pipeline of biomarker-enabled cancer immunotherapy drug candidates. The company's portfolio includes four named programs: OMX-0407 (a first-in-class SIK inhibitor in Phase I/II), IOMX-0675 (a LILRB1/LILRB2 dual-targeting antibody in IND-enabling), IOMX-0235 (a CCR9 antibody for IBD in lead optimization), and discovery-stage bispecific antibodies and T cell engagers. The pipeline is supported by the proprietary iOTarg™ systematic screening platform for identifying novel immune checkpoint targets.

Differentiator

Problem solved

Functional benefit

Products and services

• OMX-0407 An orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action combines immune sensitization and modulation of the tumor microenvironment with direct tumor cell cycle arrest. Currently in Phase I/II clinical trials for solid tumors including angiosarcoma and renal cell carcinoma.
• IOMX-0675 A dual-targeting, fully human, cross-specific high-affinity ligand-blocking antibody that simultaneously neutralizes both LILRB1 and LILRB2 (ILT2/ILT4) while sparing LILRA1 and LILRA3. Designed to re-activate innate and adaptive immunity by repolarizing the tumor microenvironment. Best-in-class potential.
• IOMX-0235 A humanized, Fc-enhanced, cynomolgus-monkey-cross-reactive monoclonal antibody targeting CCR9 for treatment of inflammatory bowel disease (Ulcerative Colitis and Crohn's Disease). Fc-engineered to efficiently deplete CCR9-positive cells with best-in-class potential in a clinically validated target class. Currently in lead optimization stage.

Quantifiable outcome

• First-in-human dose-escalation trial of OMX-0407 started March 2023 for previously treated unresectable solid tumors (NCT05826600)
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Compugen: Clinical-stage biotech using computational target discovery to identify novel immuno-oncology targets. Comparable to iOmx in its platform-driven approach to discovering next-generation IO targets beyond PD-1/PD-L1.
• F-star Therapeutics: Clinical-stage biotech developing bispecific antibodies for immuno-oncology. Comparable to iOmx's bispecific programs in engineering antibodies that simultaneously engage multiple immune pathways.
• Harpoon Therapeutics: Clinical-stage biotech developing T cell engagers and bispecifics for oncology. Comparable to iOmx's T cell engager discovery programs in targeting solid tumors with novel immune-engaging modalities.
• Surface Oncology (Coherus BioSciences): Clinical-stage biotech focused on myeloid checkpoints and novel immuno-oncology targets. Comparable to iOmx in developing therapies that target innate immune evasion mechanisms in the tumor microenvironment.
• Shattuck Labs: Clinical-stage biotech developing bispecific fusion proteins for immuno-oncology. Comparable to iOmx in developing multi-functional biologics that combine checkpoint blockade with immune activation.
• CytomX Therapeutics: Clinical-stage biotech developing masked bispecific antibodies for oncology. Comparable to iOmx in pioneering novel antibody engineering approaches and bispecific modalities for cancer immunotherapy.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing novel immune-stimulating antibody conjugates. Comparable to iOmx as a clinical-stage biotech pursuing next-generation IO mechanisms with single-agent potential.
• Immune-Onc Therapeutics: Clinical-stage biotech developing LILRB-targeted antibodies for immuno-oncology. Directly competes with iOmx's IOMX-0675 program in the same myeloid checkpoint space with overlapping LILRB1/LILRB2 mechanisms.
• Tizona Therapeutics: Clinical-stage immuno-oncology company developing LILRB-targeted antibodies. Directly comparable to iOmx in targeting the LILRB immune checkpoint family for solid tumor indications.

Broad incumbents

• MorphoSys: Established German biopharmaceutical company specializing in antibody therapeutics for oncology and inflammation. Comparable to iOmx in therapeutic area focus and antibody modality, and multiple iOmx leaders (Christine Rothe, Tiantom Jarutat) came from MorphoSys.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/iomx-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IOmx Therapeutics